Jun 14, 2022 / 05:40PM GMT
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
Okay. We're good. Thank you very much everybody, and welcome to this Tuesday session at the Goldman Sachs Healthcare Conference. My name is Chris Shibutani. I'm a member of the pharmaceutical and biotech research team. And we are very honored to have the team from Lilly come join us. The ever-dutiful IR team in the front row has been doing a great job. And our discussion today really is going to focus on the CNS division. We're so pleased to have joining us the head of that group, Anne White, who is a 26-year veteran with Lilly; and Mark Mintun as well.
So we appreciate this opportunity to perhaps enable a conversation with folks who maybe we typically don't always get to hear, which I think is a great idea. And also sort of we're kind of on a page between chapters with their business to a certain extent. And I think it's a great time to be perhaps a little bit more reflective rather than reactive so.
Eli Lilly and Co at Goldman Sachs Global Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers